What should you know about SATB2 immunohistochemistry?

Immunohistochemistry applies antibodies to thin sections of tissue. If the target marker is present, a chemical reaction creates a visible stain in the relevant cells. SATB2 is a nuclear marker that can be expressed in several tumour types, including some tumours with intestinal or bone-related differentiation. A positive stain is therefore a clue, not a stand-alone diagnosis.

The pathologist considers the strength and distribution of staining alongside the cell shape, tumour location, imaging, clinical history, and a panel of other markers. A negative result does not exclude every tumour that can express SATB2, and a positive result does not establish where a tumour began without the wider pattern.

The stain is usually performed on tissue already obtained through a biopsy or surgery; it does not require a separate procedure. Ask whether the available tissue was sufficient, which other stains were used, and what diagnosis the complete panel supports. If the tumour's origin remains uncertain, imaging, review of earlier samples, or additional sampling may be considered.

Request a copy of the pathology report and ask the team to explain unfamiliar terms such as positive, negative, focal, or diffuse. The result can help guide staging and treatment discussions, but it should be read as part of the full pathology interpretation.

SATB2 staining itself does not cause symptoms because it is performed on a laboratory sample. Contact the team that obtained the biopsy for increasing pain, redness, swelling, drainage, fever, or bleeding from the biopsy site. Seek emergency help for heavy bleeding, severe breathing difficulty, fainting, or rapidly worsening illness.

Why was SATB2 selected? Was the staining focal or widespread? Which other markers were tested? Does the complete panel support a particular origin? Is the biopsy adequate, or is further tissue needed? How does the interpretation affect staging and treatment?